Relmada Therapeutics (RLMD) Misses Q4 EPS by 10c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.27), $0.10 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• NASA selects 3 companies for 4 lunar missions worth $590M
• Freedom Capital Starts El Pollo Loco (LOCO) at Buy
• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus